Pregnancy Registry

A global pregnancy registry to assess maternal, fetal, and infant outcomes following exposure to palopegteriparatide during pregnancy and breastfeeding

Inclusion Criteria

  • Women, age 15-50
  • Received at least one dose of palopegteriparatide within 15 days prior to conception and/or during pregnancy

Exclusion Criteria

  • Pregnancies in which only the male partner is exposed to at least one dose of palopegteriparatide

For additional study information and for inclusion/exclusion criteria: Healthcare providers may visit ClinicalTrials.gov (NCT07345494).

Learn more Frequently Asked Questions

Ascendis Pharma does not recommend or endorse using its medications in a way that conflicts with FDA-approved labeling.